Silverback Therapeutics Inc. (SBTX) News

Silverback Therapeutics Inc. (SBTX): $5.87

0.06 (+1.03%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add SBTX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#175 of 385

in industry

Filter SBTX News Items

SBTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SBTX News From Around the Web

Below are the latest news stories about SILVERBACK THERAPEUTICS INC that investors may wish to consider to help them evaluate SBTX as an investment opportunity.

Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment

ARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ: SBTX) in an all-stock transaction, with a new entity operating under the ARS Pharmaceuticals name and trade on NASDAQ under the SPRY symbol. The combined company will focus on neffy, ARS's investigational epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. The combined entity is expected to have approximately $265 million in cash and equivalents at closing. Also Read: Silverback Therapeutics Ax

Yahoo | July 22, 2022

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

SEATTLE & SAN DIEGO, July 21, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. T

Yahoo | July 21, 2022

What You Need To Know About Silverback Therapeutics, Inc.'s (NASDAQ:SBTX) Investor Composition

The big shareholder groups in Silverback Therapeutics, Inc. ( NASDAQ:SBTX ) have power over the company. Large...

Yahoo | June 22, 2022

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SEATTLE, May 17, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.

Yahoo | May 17, 2022

JonesTrading Keeps Their Hold Rating on Silverback Therapeutics (SBTX)

JonesTrading analyst Soumit Roy maintained a Hold rating on Silverback Therapeutics (SBTX – Research Report) on May 13. The company's shares closed last Friday at $2.96, close to its 52-week low of $2.80. According to TipRanks.com, Roy is a 3-star analyst with an average return of 3.2% and a 28.5% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Silverback Therapeutics with a $3.43 average price target, an 11.0% upside from current levels. In a report issued on May 13, H.C.

Christine Brown on TipRanks | May 15, 2022

H.C. Wainwright Keeps a Hold Rating on Silverback Therapeutics (SBTX)

E ratio of….

Brian Anderson on TipRanks | May 13, 2022

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

SEATTLE, May 12, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Yahoo | May 12, 2022

Is Silverback Therapeutics (NASDAQ:SBTX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | May 8, 2022

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

SEATTLE, March 31, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today provided an update on strategic priorities and reported financial results for the fourth quarter and full year ended December 31, 2021.

Yahoo | March 31, 2022

Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

SEATTLE, February 24, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.

Yahoo | February 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!